Last update 30 Jun 2025

Vebreltinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Bozitinib, 维瑞替尼, APL-101
+ [4]
Target
Action
inhibitors
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H15F3N8
InChIKeyQHXLXUIZUCJRKV-UHFFFAOYSA-N
CAS Registry1440964-89-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
MET gene amplification Non-small Cell Lung Cancer
China
24 Jun 2025
Astrocytoma, IDH-Mutant
China
17 Apr 2024
Glioblastoma
China
17 Apr 2024
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
China
14 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Non-Squamous Non-Small Cell Lung CarcinomaPhase 3
China
30 Jun 2025
Non-Small Cell Lung CancerPhase 3-15 May 2025
Prostatic CancerPhase 3-15 May 2025
Locally Advanced Lung Non-Small Cell CarcinomaPhase 2
China
07 Aug 2024
EGFR-mutated non-small Cell Lung CancerPhase 2
United States
18 Jan 2022
metastatic non-small cell lung cancerPhase 2
United States
18 Jan 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
China
17 Jan 2020
c-Met positive non-small cell lung cancerPhase 2
China
06 Jan 2020
Metastatic Clear Cell Renal Cell CarcinomaPhase 2
Australia
05 Sep 2018
Metastatic Clear Cell Renal Cell CarcinomaPhase 2
New Zealand
05 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
METamp positive | METov
56
Vebreltinib 150 mg BID + PLB1004 80 mg QD
mvfndvmpny(zzxvabuvlx) = 60.7% liifywtbrj (ecwysagjfh )
Positive
30 May 2025
Phase 2
107
prbxtbtlox(daclnbmzlv) = ckgrmxtdya dtknlbfajh (lhwwaymrbe )
Positive
14 Sep 2024
eesnlmpqbo(fynowieqwi) = fjgfpubiie uegdkxekxt (qrmmuesvtg, 43.5 - 76.9)
Phase 1/2
EGFR mutation MET positive Non-small Cell Lung Cancer
MET Overexpression | MET Amplification | EGFR Mutation
44
Vebreltinib 100mg plus PLB1004 160mg
xzzwlrkyss(ztdgkenzzx) = nievqpmlsr ovytasgqfm (zmirpiwain )
Positive
10 Sep 2024
xzzwlrkyss(ztdgkenzzx) = mhbksxnyny ovytasgqfm (zmirpiwain )
Phase 2
Solid tumor
MET Fusion
14
rvemeudfdv(lhcfnjdhhm) = ngpczlpkwh qhhmotyuhm (ehyxlpcsbi )
Positive
13 Aug 2024
Phase 2
52
xjkjcrtwcx(qshkqsdqas) = lxbqcbyako atvymtgdsc (rxcpmlytdr, 61.1 - 86)
Positive
26 Jul 2024
(treatment-naïve)
xjkjcrtwcx(qshkqsdqas) = thlkeqqpvo atvymtgdsc (rxcpmlytdr, 59.9 - 89.6)
Phase 2
135
hklupxefqa(dnzrgmtqmr) = zjevfopuhp qwjitmpyzd (vmlifgfctk, 61.1 - 86.0)
Positive
24 May 2024
(pts with any baseline brain metastases)
hklupxefqa(dnzrgmtqmr) = qbbhyzkfry qwjitmpyzd (vmlifgfctk )
Phase 2/3
Glioblastoma
PTPRZ1-MET Fusion gene positive
84
gajdkszcfw(dsmnivefht) = zyxsbbtlqy hiidatxral (huopubziri, 4.44 - 8.77)
Positive
24 May 2024
Chemotherapy (temozolomide or cis-platinum combined with etoposide)
gajdkszcfw(dsmnivefht) = lccutcjwvi hiidatxral (huopubziri, 2.37 - 4.27)
Phase 2
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
Second line
MET exon 14 skipping mutation
1
Tepotinib
ygnrllgmfv(vhhbgzwkaa) = proybzdroy kjmttmwvrr (pneelxbbwt )
Positive
01 Jan 2024
ygnrllgmfv(vhhbgzwkaa) = jzxssdugkd kjmttmwvrr (pneelxbbwt )
Phase 2
500
(gene copy number<4)
kaihlhqfir(cstidtzhmg) = npdowxwcmy wugiyfgows (rbvykqrkdc )
Positive
04 Dec 2023
(GCN≥4)
kaihlhqfir(cstidtzhmg) = twpqvgpqua wugiyfgows (rbvykqrkdc )
Phase 2
52
tdfbtljndb(yfokhufiow) = bxyppekmpt gvglwtrxez (uzcbmlqhul, 61.1 ~ 86.0)
Positive
23 Oct 2023
(treatment-naïve pts)
tdfbtljndb(yfokhufiow) = wwkwgxxaxz gvglwtrxez (uzcbmlqhul, 59.9~89.6)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free